SBT1.2 Antibody
Description
Clarification of Terminology
-
SBT5.2: A subtilase enzyme critical for processing IgG antibodies (e.g., 2F5) in plants like Nicotiana benthamiana .
-
SBT-100: A bispecific single-domain antibody (sdAb) targeting KRAS and STAT3, developed by Singh Biotechnology (SBT) .
Key Distinction:
| Term | Description | Role | Source |
|---|---|---|---|
| SBT5.2 | Serine protease | Processes IgG antibodies in plants | |
| SBT-100 | Bispecific sdAb | Targets KRAS/STAT3 for cancer therapy |
Potential Misinterpretations
The user may have conflated "SBT1.2" with:
-
SBT5.2: A subtilase enzyme, not an antibody, involved in IgG degradation in plant systems .
-
SBT-100: A therapeutic antibody targeting intracellular oncogenic proteins .
Research Gaps and Recommendations
No primary or secondary sources describe "SBT1.2 Antibody." This suggests:
-
Nomenclature Error: The term may refer to an experimental compound not yet published or a misidentified variant (e.g., SBT5.2 or SBT-100).
-
Proprietary Designation: If "SBT1.2" is a proprietary antibody under development, publicly available data may be limited.
Related Antibody Research
For context, notable antibodies in the sources include:
Product Specs
Constituents: 50% Glycerol, 0.01M PBS, pH 7.4
Target Background
- Research has identified Arabidopsis GT2-LIKE 1 (GTL1) as a transcriptional repressor of STOMATAL DENSITY AND DISTRIBUTION 1 (SDD1). SDD1, in turn, is a negative regulator of stomatal density. PMID: 21691149
